C11-TDP43-A382T
The cell line is not validated yet.
UQi001-A-1
General
Cell Line |
|
| hPSCreg name | UQi001-A-1 |
| Cite as: | UQi001-A-1 (RRID:CVCL_D0P9) |
| Alternative name(s) |
C11-TDP43-A382T
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UQi001-A (C11-WT) CBIGi001-A-22 (TARDBP-A382T/AIW002-02, IPSC0089) CBIGi001-A-23 (TARDBP-G348C/AIW002-02, IPSC0090) WTSIi018-B-18 (Kolf 2.1 J (TARDBP M337V WT/SNV)) WTSIi018-B-21 (Kolf 2.1 J (TARDBP M337V SNV/SNV)) WTSIi018-B-22 (Kolf 2.1 J (TARDBP Q331K WT/SNV)) WTSIi018-B-23 (Kolf 2.1 J (TARDBP Q331K SNV/SNV)) CBIGi022-A-1 (SOD1 I114T correction (CBIGi022-A), IPSC0029) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis UCSFi001-A-74 (FUS-P525L HET 2D1) UCSFi001-A-75 (FUS-P525L HOM 2D2) CBIGi001-A-19 (IPSC0084, SOD1 G93A/AIW002-02) CBIGi001-A-31 (IPSC0103, C9ORF72-KO/AIW002-02) CBIGi001-A-37 (IPSC0109, FUS-H517Q/AIW002-02) CBIGi001-A-38 (IPSC0110, FUS-KO/AIW002-02) WTSIi018-B-24 (Kolf 2.1 J (FUS R495X WT/SNV)) WTSIi018-B-25 (Kolf 2.1 J (FUS R495X SNV/SNV)) WTSIi018-B-26 (Kolf 2.1 J (FUS R521H WT/SNV)) WTSIi018-B-27 (Kolf 2.1 J (FUS R521H SNV/SNV)) CBIGi001-A-7 (IPSC0068, OPTN-KO/AIW002-02) UCSFi001-A-72 (FUS-R521G HET 2B10, LSUHSi004-A-72) UCSFi001-A-73 (FUS-R521G HOM 1D9) CBIGi001-A-11 (IPSC0075, PRKN Y143D/AIW002-02) CBIGi001-A-12 (PRKN-V393D/AIW002-02, IPSC0076) CBIGi001-A-13 (IPSC0078, SCARB2-KO/AIW002-02) CBIGi001-A-14 (IPSC0079, SH3GL2-KO/AIW002-02) CBIGi001-A-15 (SNCA A30P/AIW002-02, IPSC0080) CBIGi001-A-16 (IPSC0081, SNCA A53T/AIW002-02) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) CBIGi001-A-17 (IPSC0082, SNCA E46K/AIW002-02) BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) CBIGi001-A-18 (IPSC0083, SNCA-KO/AIW002-02) CBIGi001-A-21 (IPSC0086, SMPD-KO/AIW002-02) BIONi010-C-25 (BIONi010-C heterozygous TREM2 KO) CBIGi001-A-24 (TMEM163-KO/AIW002-02, IPSC0096) CBIGi001-A-25 (IPSC0097, TMEM175-KO/AIW002-02) BIONi010-C-70 (BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation) BIONi010-C-71 (BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation) CBIGi001-A-26 (USP19-KO/AIW002-02, IPSC0098) CBIGi001-A-28 (IPSC0100, ASAH1-KO/AIW002-02) CBIGi001-A-29 (ATAXIN3-KO/AIW002-02, IPSC0101) CBIGi001-A-30 (BIN3-KO/AIW002-02, IPSC0102) CBIGi001-A-33 (CLCN3-KO/AIW002-02, IPSC0105) CBIGi001-A-34 (CTSB-KO/AIW002-02, IPSC0106) CBIGi001-A-35 (FAM49B(CYRIB)-KO/AIW002-02, IPSC0107) CBIGi001-A-39 (IPSC0111, GALC-KO/AIW002-02) CBIGi001-A-40 (IPSC0112, GBA-KO/AIW002-02) CBIGi001-A-41 (IPSC0113, GBAP1_promoter-KO/AIW002-02) BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27) CBIGi001-A-42 (IGSF9B-KO/AIW002-02, IPSC0114) |
| Last update | 16th May 2023 |
| User feedback | |
Provider |
|
| Generator | The University of Queensland (UQ) |
| Owner | The University of Queensland (UQ) |
| Distributors | |
| Derivation country | Australia |
External Databases |
|
| BioSamples | SAMEA113429835 |
| Cellosaurus | CVCL_D0P9 |
| Wikidata | Q123033758 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46XY
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA113429809 |
Ethics
Also have a look at the ethics information for the parental line
UQi001-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
UQi001-A.
|
|
| Passage number reprogrammed | 41 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ Plus
|
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XY
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.